Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Alpha-synuclein-induced neuroinflammation is a key pathogenic mechanism in synucleinopathies. Misfolded and aggregated alpha-synuclein activates microglia via TLR2/TLR4, leading to NF-κB activation and NLRP3 inflammasome assembly. This results in the release of pro-inflammatory cytokines (IL-1β, IL-18, TNFα) that contribute to neuronal damage and death. Peripheral immune cell infiltration and dysregulation of microRNAs like miR155 further exacerbate the inflammatory response. Therapeutic strategies aim to reduce alpha-synuclein aggregation, modulate immune signaling pathways, and protect neurons from inflammation-mediated injury.
Inhibition of alpha-synuclein aggregation; modulation of TLR signaling; inhibition of NF-kappaB; suppression of NLRP3 inflammasome; regulation of inflammatory cytokine production; modulation of microRNA expression.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Neuroinflammation (alpha-synuclein-induced).